Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFNT 111

Next Previous
Drug Profile

AFNT 111

Alternative Names: AFNT-111; FHA11KRASG12V-TCR; T-cell Receptor-engineered T Cells; TCR T Cells; TCR-modified T Cells

Latest Information Update: 10 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Affini-T Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer

Most Recent Events

  • 22 Oct 2025 Fred Hutchinson Cancer Center suspends a phase I trial in non-small cell lung cancer, pancreatic cancer, colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06043713)
  • 15 Dec 2023 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06043713)
  • 15 Dec 2023 Phase-I clinical trials in Non-small cell lung cancer (Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT06043713)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top